Showing results (51-60 of 161) with videos related to

Sort By:
Pageof 17
Cancers|July 13, 2024
Comparing Two Targeted Biopsy Schemes for Detecting Clinically Significant Prostate Cancer in Magnetic Resonance Index Lesions: Two- to Four-Core versus Saturated Transperineal Targeted BiopsyJuan Morote, Nahuel Paesano, Natàlia Picola, et al.
BJU International|June 25, 2009
Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosisJacques Planas, Enrique Trilla, Carles Raventós, et al.
Cancers|August 26, 2022
Multiparametric MRI for Staging of Prostate Cancer: A Multicentric Analysis of Predictive Factors to Improve Identification of Extracapsular Extension before Radical ProstatectomyMarina Triquell, Lucas Regis, Mathias Winkler, et al.
Urologia Internationalis|August 5, 2006
Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancerJuan Morote, Salvador Esquena, José M Abascal, et al.
Plos One|April 13, 2019
siRNA-silencing of CD40 attenuates unilateral ureteral obstruction-induced kidney injury in miceAlonso Narváez, Roser Guiteras, Anna Sola, et al.
Clinical Genitourinary Cancer|December 5, 2017
Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist TherapyJuan Morote, Inma Comas, Jacques Planas, et al.
European Journal of Radiology|February 19, 2021
The position of urethrovesical anastomosis after robotic radical prostatectomy assessed by MRI predicts early functional recovery: A cohort analyses from a randomized clinical trialLucas Regis, Aina Salazar, Jacques Planas, et al.
Scandinavian Journal of Urology|January 11, 2019
The role of negative magnetic resonance imaging: can we safely avoid biopsy in P.I.-R.A.D.S. 2 as in P.I.-R.A.D.S. 1?Lucas Regis, Ana Celma, Jacques Planas, et al.
European Urology Focus|July 30, 2017
Factors Predicting the Off-treatment Duration in Patients with Prostate Cancer Receiving Degarelix as Intermittent Androgen Deprivation TherapyPer-Anders Abrahamsson, Laurent Boccon-Gibod, Juan Morote, et al.
The American Journal of Pathology|February 25, 2003
PTOV-1, a novel protein overexpressed in prostate cancer, shuttles between the cytoplasm and the nucleus and promotes entry into the S phase of the cell division cycleAnna Santamaría, Pedro L Fernández, Xavier Farré, et al.
Pageof 17